SFI
MRKR icon

Susquehanna Fundamental Investments’s Marker Therapeutics MRKR Stock Holding History

Susquehanna Fundamental Investments’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,925
Closed -$18K – 1633
2021
Q4 		$18K Sell
1,925
-1,870
-49% -$24.8K ﹤0.01% 1395
2021
Q3 		$64K Sell
3,795
-520
-12% -$10.7K ﹤0.01% 1651
2021
Q2 		$120K Buy
+4,315
New +$114K ﹤0.01% 1552

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $546M AUM 24.08% 1-Year Est. Return

Susquehanna Fundamental Investments's MRKR Position: Q1 2022 in Review

Susquehanna Fundamental Investments sold out of Marker Therapeutics (MRKR) in Q1 2022, closing a stake of 1,925 shares — an estimated $18K sold.

Susquehanna Fundamental Investments first reported a position in MRKR in Q2 2021 and held it in 3 quarters. The position peaked at $120K in Q2 2021. 49 funds tracked by Wall St. Rank hold MRKR as of Q1 2022.

  • Susquehanna Fundamental Investments reported no remaining Marker Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 1,925 Marker Therapeutics shares in Q1 2022, an estimated $18K.
  • Susquehanna Fundamental Investments first reported a position in Marker Therapeutics in Q2 2021 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's Marker Therapeutics position peaked at $120K in Q2 2021.
  • 49 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.